Pharma News

Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Susvimo® (ranibizumab) for the treatment of neovascular age-related macular degeneration (nAMD). If the European Commission grants final approval, Susvimo will become the first continuous drug-delivery treatment for nAMD in the European Union.

The U.S. Food and Drug Administration (US FDA) has issued a Warning Letter to Almon Healthcare Private Limited, Ahmedabad, Gujarat, after identifying significant violations of Current Good Manufacturing Practice (CGMP) regulations at its active pharmaceutical ingredient (API) manufacturing facility during an inspection conducted from February 9–13, 2026. The warning letter was issued on July 13, 2026.

Novo Nordisk has announced that it has filed a lawsuit against Eli Lilly and Company in the United States, alleging that Lilly's advertising campaigns for its GLP-1 medicines are misleading and do not present complete scientific information.

Global pharmaceutical company Sanofi has received a Public Reprimand from the Prescription Medicines Code of Practice Authority (PMCPA) after a complaint was filed by Pfizer.

The PMCPA investigated the case (CASE/0689/08/25) and found that Sanofi had breached several rules of the 2024 ABPI Code of Practice, which sets standards for how pharmaceutical companies should promote their medicines in the UK.

The Indian Council of Medical Research (ICMR) has transferred three indigenous healthcare technologies to leading Indian pharmaceutical and vaccine manufacturers for further development, manufacturing, and commercialization. The initiative is aimed at accelerating affordable healthcare solutions while strengthening the country's self-reliance in medical innovation.

Cipla Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., located in Central Islip, Long Island, New York, USA.

The inspection was carried out from July 13 to July 17, 2026 (EDT) as part of the USFDA's routine regulatory oversight of pharmaceutical manufacturing facilities.

A new survey has uncovered significant knowledge gaps among families with a history of type 1 diabetes (T1D), highlighting misconceptions that may delay early screening and diagnosis despite their increased risk of developing the disease.

The survey, titled "The Family Factor: A T1D Risk Awareness Survey," was conducted by global diabetes nonprofit Beyond Type 1 and commissioned by Sanofi. It focused on adults and caregivers with a first-degree family member living with type 1 diabetes.

An international research team led by the Medical University of Vienna has investigated a new peptide derived from cone snail venom which significantly reduced inflammation-induced pain in an animal model. Crucially, its effect takes hold immediately after subcutaneous injection, whereas previously known cone snail peptides must be administered directly into the cerebrospinal fluid.